Breast Density and
Mammography Sensitivity
A study funded by NCI and the American Cancer Society published in the October
5 Journal of the National Cancer Institute, shows that increased breast tissue
density and rapid tumor growth are associated with decreased mammogram
sensitivity and missed cancers in women aged 40-49. Mammography is recommended
for women who are in their 40s and older, but is less sensitive at detecting
breast cancer in women at the younger end of this scale. To determine specific
reasons for the lack of sensitivity, the research team, led by Dr. Diana S.M.
Buist at Group Health Cooperative in Seattle, studied 576 women from the Breast
Cancer Screening Program who were diagnosed with invasive breast cancer from
1988-1993. The women completed breast cancer risk factor questionnaires upon
enrollment in the study and at the time of each subsequent mammogram; all
diagnosed tumors were evaluated for the rate of tumor growth. At 12 and 24
months following the subject's baseline mammogram, researchers evaluated
mammogram sensitivity while accounting for menopause status, body mass index,
family history of breast cancer, hormone therapy use, time since last
mammogram, tumor markers, breast density, and quality of mammographic images.
Researchers found that breast density accounted for most of the reduction (68
percent) in mammogram sensitivity in women aged 40-49 when looking at cancers
occurring within 12 months. However, when these women were evaluated at 24
months, breast density accounted for 38 percent of the decline in sensitivity,
while rapid tumor growth accounted for a 30 percent reduction. Says Dr. Stephen
Taplin of NCI, who also worked on the study, "These data begin to provide
greater insight into how to improve mammography for women ages 40-49, and why a
2-year interval may be less effective. However, it is a study of detection, not
mortality. Improvements must be tested for their effect on mortality."
Drug Combo Improves Outcomes in Prostate Cancer
Metastatic prostate cancer, found in 10-20 percent of men diagnosed with the
disease each year, has a median survival period of less than a year. Patient
care focuses on pain relief via radiation, narcotics, corticosteroids, and the
chemotherapy drug mitoxantrone. However, two recent studies in the October 7
New England Journal of Medicine have found that a new chemotherapy regimen can
improve survival and quality of life for these men. In the first study, a
combination of docetaxel with prednisone every 3 weeks, compared with
mitoxantrone with prednisone at the same frequency, improved median survival
(up to 18.9 months) and quality of life, while decreasing pain and serum PSA
levels. Led by researchers at the University of Toronto and the Southwest
Oncology Group, the study was sponsored by Aventis. Patients who received
docetaxel showed better outcomes than those who received mitoxantrone, but the
authors note that it was "at the cost of a higher incidence of adverse
effects," including neutropenic fevers, cardiovascular and neurologic events,
nausea, and metabolic disturbances. The second study compared 3-week doses of
docetaxel with estramustine to 3-week doses of mitoxantrone with prednisone.
The trial, led by researchers at Columbia University and cosponsored by Aventis
and NCI, found that the docetaxel combination increased median survival to 17.5
months and lowered mortality by 20 percent. The authors noted an increased rate
of adverse events with docetaxel similar to those in the first study, and
wrote, "These factors must be balanced when one is considering...first-line
therapy for men with metastatic, androgen-independent prostate cancer."
Effectiveness of Shorter Therapy for Wilms' Tumor
Researchers from the International Society of Paediatric Oncology found that
reducing the course of postoperative chemotherapy to 4 weeks produced
equivalent survival rates compared with the standard 18-week treatment for
stage I Wilms' tumor. Results of their 7-year study were published in the
October 2 Lancet. Wilms' tumor, a type of kidney cancer that affects infants and
children, is considered curable in most cases, but common chemotherapy drugs
have been associated with toxic effects to the liver and heart. Reducing
intensity of chemotherapy by shortening treatment may reduce side effects and
cost. Researchers enrolled and randomized 410 patients between the ages of 6
months and 18 years with stage I intermediate-risk or anaplastic Wilms' tumor
between 1993-2000. Event-free survival at 2 years was 91.4 percent in the
standard group and 88.8 percent in the experimental group. Event-free survival
at 5 years was similar: 88.3 percent in the standard group and 87 percent in
the experimental group. The authors wrote that "reduction of postoperative
chemotherapy is feasible for patients with stage I intermediate-risk or
anaplastic Wilms' tumor while maintaining 2-year, event-free survival at about
90 percent and 5-year overall survival at about 95 percent."
Arylamines and Bladder Cancer Risk in Nonsmokers
Results of a recent study indicate that exposure to arylamines, a family of
known carcinogens previously associated with the increased risk of bladder
cancer in smokers, is also a risk factor for bladder cancer in nonsmokers. The
report, by Dr. Jinping Gan and colleagues at Massachusetts Institute of
Technology, was published in the October 6 Journal of the National Cancer
Institute. Metabolites of certain drugs and pesticides, arylamines are found in
cigarette smoke, permanent hair dyes, and other environmental sources. Studies
have shown that cigarette smoking may contribute to at least 50 percent of
current bladder cancer cases in the United States. However, previous research
has also indicated that 4-ABP, a specific arylamine, is associated with bladder
cancer in nonsmokers. In this study, funded in part by NCI, researchers
quantitatively measured the levels of arylamine adducts in the blood of 298
subjects with confirmed bladder cancer and 308 control subjects to assess
exposures to nine different arylamines. Their results indicated that in
addition to 4-ABP, three other arylamines may be independent risk factors for
bladder cancer in nonsmokers. The authors note that exposure to arylamines may
be the causal factor for most cases of bladder cancer in humans and conclude
that because "arylamines may account for a substantial proportion of bladder
cancers among the general population, identification of the environmental
sources of these compounds is needed."
|